One of AstraZeneca’s key drugs for its ambitious sales target Tagrisso (osimertinib) has hit its marks in a Phase III test for certain lung cancer patients--…

George Freeman has left the post of minister for life sciences as part of a reshuffle initiated by the new U.K. prime minister in the wake of the Brexit vote.

Kite Pharma has said it has no concerns with its recently enrolled experimental CAR-T trial that is using a chemo drug now dropped by rival Juno after it…

Amgen took one step closer to approval for its biosimilar of the world’s biggest-selling drug last night, but analysts don’t see it hitting the market this…

Shire has been given a key U.S. approval for its new eye disease drug lifitegrast nearly a year after it was rejected by the FDA, and can now look to make good…

As the fallout continues from the shock announcement on Thursday that 3 patients died while being tested under Juno’s experimental CAR-T program, rival Kite…

Juno Therapeutics had hoped to have a first approval for its lead candidate next year. But that looks unlikely to happen as its pivotal trial is put on hold.

Confidentially, EMA head Guido Rasi has said that a move from the U.K. to leave the EU was “a nightmare with immediate consequences,” although publicly the…